Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harmony Biosciences Holdings, Inc. filings document a commercial-stage pharmaceutical issuer focused on rare neurological diseases and its WAKIX-centered operating results. Form 8-K reports furnish quarterly and annual financial results, preliminary net product revenue, revenue guidance, investor presentations, and clinical-program updates.
Governance filings include definitive proxy materials for annual meeting matters, board elections, executive compensation, and shareholder voting procedures. Material-event reports also record executive appointments, separations, compensatory arrangements, board changes, Regulation FD disclosures, and exhibit-based updates related to the company’s business and pipeline.
Harmony Biosciences Holdings, Inc. director Germano Geno J received a grant of stock options as equity compensation. The award covers 21,231 options for common stock at an exercise price of $30.76 per share and expires on May 14, 2036. These options vest in 36 equal monthly installments beginning on June 14, 2026. Following this grant, he holds 21,231 stock options directly, with no open-market share purchases or sales reported in this filing.
Harmony Biosciences Holdings, Inc. director Germano Geno J filed an initial Form 3, which is the SEC’s required first insider ownership report for company officers, directors, and large shareholders. This filing lists him as a reporting person but does not show any specific share transactions.
Harmony Biosciences Holdings, Inc. reported that director Linda M. Szyper received a grant of stock options covering 21,872 shares of common stock at an exercise price of $30.76 per share. These options expire on May 14, 2036 and represent compensation rather than an open‑market purchase.
The option vests in full on the earlier of May 14, 2027 or the date of the next annual meeting following the grant, as long as Szyper continues in service through that date. Following this award, she holds 21,872 derivative securities directly tied to Harmony Biosciences common stock.
Harmony Biosciences Holdings, Inc. director Philip Ron M reported a compensation-related grant of stock options. He was awarded 21,872 stock options for Common Stock with an exercise price of $30.76 per share, all held directly after the grant.
The options expire on May 14, 2036 and will vest in full on the earlier of May 14, 2027 or the date of the next annual meeting following the grant, subject to his continued service. This filing reflects an acquisition of derivative securities, not an open-market share purchase or sale.
Harmony Biosciences Holdings director Graf R. Mark received a new stock option grant covering 21,872 shares of common stock. The options have an exercise price of $30.76 per share and expire on May 14, 2036. They vest in full on the earlier of May 14, 2027 or the next annual meeting, subject to his continued service. After this grant, he holds 21,872 stock options directly according to this filing.
Harmony Biosciences Holdings, Inc. director Juan A. Sabater received a grant of stock options as part of his compensation. He was awarded options for 21,872 shares of common stock at an exercise price of $30.76 per share, giving him the right to buy shares at that price in the future. These options vest in full on the earlier of May 14, 2027 or the date of the next annual meeting after the grant, as long as he continues to serve through that vesting date. After this grant, he holds 21,872 stock options directly.
Harmony Biosciences Holdings, Inc. director Gary Sender reported a grant of stock options covering 21,872 shares of common stock. The options have an exercise price of $30.76 per share and expire on May 14, 2036. They vest in full on the earlier of May 14, 2027 or the next annual meeting following the grant date, subject to continued service. This is a compensation-related award rather than an open-market trade.
Harmony Biosciences Holdings, Inc. chief medical officer Kumar Budur exercised 18,750 restricted stock units into common stock and had 8,882 shares withheld by the company to cover income tax obligations tied to the vesting. These are compensation-related, non‑market transactions rather than open‑market buying or selling.
Following the transactions, Budur directly owns 24,115 shares of common stock. The filing also corrects previously misstated common stock and derivative holdings, and confirms that the RSU award granted on May 1, 2024 vests in four equal annual installments beginning May 1, 2025.
Harmony Biosciences Holdings, Inc. reported that Chief Financial Officer Glenn Reicin received a grant of stock options covering 164,309 shares of common stock. The options have an exercise price of $29.29 per share and expire on April 14, 2036.
According to the vesting terms, 25% of the underlying shares vest on April 14, 2027, with the remaining shares vesting quarterly until the fourth anniversary of the grant date, subject to his continued service. Following this award, Reicin holds 164,309 stock options directly.
Harmony Biosciences Holdings, Inc. reported that its Chief Financial Officer, Glenn Reicin, filed an initial Form 3 insider ownership report. The filing lists no stock transactions or derivative positions and shows zero shares bought, sold, or otherwise transacted at this time.